image

The best stocks to buy since 1993

Latest issue now available

BTG - Shares soar on Varisolve news

May 2005

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • BGC
  • Price:
  • 136.5p
The shares surged 30% to a seven month high after BTG provided a positive update on Varisolve, its treatment for varicose veins. This said it will be resubmitting plans to US regulators, with a view to getting clinical trials of the experimental drug started again. The key update on Varisolve underlined that having provided a full response to the US Food and Drug Administration, the FDA has confirmed they will not be requesting any additional studies and have agreed conceptually to plans for new clinical trials. If the FDA allows the US phase II trials to resume, filing will take place in 2007 with a potential launch in 2009. In advance of that, BTG is continuing discussions with potential partners in order to conclude a  glo ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

LIMITED PERIOD OFFER

SUBSCRIBE TODAY AND SAVE £40 WITH OFFER CODE 40OFFSCSW

To access our archive of articles and to receive current issues you need to subscribe